5-amino-1MQ — compound monograph
Small-molecule nicotinamide N-methyltransferase inhibitor. Preclinical only. The Institute assesses 3 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- 5-amino-1MQ
- Compound class
- Small-molecule nicotinamide N-methyltransferase inhibitor
- Assessment series
- Mitochondrial and metabolic cofactors
- Synonyms and codes
- 5-amino-1-methylquinolinium · 5-amino-1MQ iodide · NNMT inhibitor 5-amino-1MQ
- Route as evaluated
- Oral and intraperitoneal in preclinical studies; oral in research contexts
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- not consistently assigned; the iodide salt is commonly listed as 5304-48-3
- Molecular formula
- C10H11IN2 (iodide salt); C10H11N2⁺ (cation)
- Average mass
- 286.11 (iodide salt); 159.21 (cation)
- Monoisotopic mass
- 286.00
- ATC classification
- not assigned
§1.3Sequence and structural notes
A permanently charged quaternary quinolinium cation supplied as a salt, usually the iodide. Its permanent positive charge is pharmacologically consequential: quaternary cations cross membranes poorly, which is directly relevant to a compound whose target is intracellular.
§1.4Assessment status
The Institute assesses 5-amino-1MQ across 3 indications and grades the strongest of them at very low certainty. No human study has been identified.
Table 1. Assessed outcomes for 5-amino-1MQ, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Biological ageing and healthspan endpoints | No human trial identified | Very low | 0 |
| Obesity and overweight in adults | No human trial of any kind identified | Very low | 0 |
| Type 2 diabetes mellitus | No human trial identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.